New York, NY — February 6, 2026 — Leads & Copy — Pfizer Inc. has launched its program on TrumpRx, aiming to enhance the affordability and accessibility of its innovative medicines for millions of Americans. The program, effective immediately, offers Americans access to over 30 medicines at significantly discounted prices.
This initiative is part of Pfizer’s Most Favored Nation (MFN) agreement with the U.S. government, designed to allow patients to benefit from lower prescription medicine prices, while maintaining America’s leadership in pharmaceutical innovation.
According to Pfizer Chairman and Chief Executive Officer Albert Bourla, Americans have been bearing a disproportionate share of the global cost of innovation. Pfizer is supporting the administration in ensuring affordability for American patients, while preserving America’s position at the forefront of medical innovation.
The TrumpRx platform will provide uninsured or insured American patients who opt to self-pay savings of up to 85%, and an average of 50%, on most of Pfizer’s primary care treatments and select specialty brands. This will allow consumers to make choices that suit their needs. The medicines included in the program treat diseases impacting over 100 million patients, including migraines, rheumatoid arthritis, menopause, atopic dermatitis, and overactive bladder.
Pfizer is collaborating with GoodRx to give patients seeking affordable treatments more flexibility and options, including the ability to use coupons at almost any U.S. pharmacy or choose at-home delivery. A complete list of participating Pfizer brands is available online.
Pfizer will also continue to expand PfizerForAll, a direct-to-consumer platform launched in 2024, to offer more ways for people to be in charge of their health care.
Pfizer applies science and resources to bring therapies to people that extend and significantly improve their lives. The company collaborates with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world.
The information contained in this release is as of February 5, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.
Source: Pfizer
